Literature DB >> 17094790

Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans.

Noboru Yamaguchi1, Toshio Kukita, Yin-Ji Li, Jose Guillermo Martinez Argueta, Toshiyuki Saito, Shigemasa Hanazawa, Yoshihisa Yamashita.   

Abstract

Previous epidemiologic studies have suggested that periodontal disease is closely related to obesity and glucose tolerance. As the level of adiponectin, an adipocyte-derived cytokine, in plasma had been reported to decrease in obese and type 2 diabetes patients, we explored the role of adiponectin in the etiology of periodontitis using the D clone of RAW264, a clone that exhibits highly efficient osteoclast formation, to determine whether adiponectin acts as a regulatory molecule in osteoclast formation stimulated by lipopolysaccharide of periodontopathic bacteria. We observed that adiponectin acted as a potent inhibitor of osteoclast formation stimulated by Toll-like receptor 4 (TLR4) ligand and receptor activator of NF-kappaB ligand (RANKL). Because NF-kappaB is an important transcription factor in osteoclast formation, we examined the effect of adiponectin on its transcriptional activity. A luciferase assay showed that adiponectin was able to inhibit the TLR4-mediated NF-kappaB activity in RAW264 cells. In addition, we observed that the cytokine was actually able to inhibit TLR4-mediated expression of the gene for inducible nitric oxide synthase and production of nitric oxide in the cells. These observations strongly suggest that adiponectin may function as a negative regulator of lipopolysaccharide/RANKL-mediated osteoclast formation in periodontal disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094790     DOI: 10.1111/j.1574-695X.2006.00164.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  27 in total

1.  Sustained release of adiponectin improves osteogenesis around hydroxyapatite implants by suppressing osteoclast activity in ovariectomized rabbits.

Authors:  En Luo; Jing Hu; Chongyun Bao; Yunfeng Li; Qisheng Tu; Dana Murray; Jake Chen
Journal:  Acta Biomater       Date:  2011-10-25       Impact factor: 8.947

Review 2.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway.

Authors:  Tingting Luo; Hongrui Liu; Wei Feng; Di Liu; Juan Du; Jing Sun; Wei Wang; Xiuchun Han; Jie Guo; Norio Amizuka; Xianqi Li; Minqi Li
Journal:  Cell Prolif       Date:  2016-11-21       Impact factor: 6.831

4.  [Adiponectin as target in rheumatoid arthritis].

Authors:  E Neumann; K W Frommer; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

Review 5.  Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass.

Authors:  M P Hage; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-09-06       Impact factor: 4.507

6.  Central adiponectin administration reveals new regulatory mechanisms of bone metabolism in mice.

Authors:  Yuwei Wu; Qisheng Tu; Paloma Valverde; Jin Zhang; Dana Murray; Lily Q Dong; Jessica Cheng; Hua Jiang; Maribel Rios; Elise Morgan; Zhihui Tang; Jake Chen
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-04-29       Impact factor: 4.310

7.  Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.

Authors:  Sila Cagri Isler; Fatma Soysal; Erkan Ozcan; N Isıl Saygun; F Berrin Unsal; Emre Baris; Rahsan Ilikci
Journal:  Clin Oral Investig       Date:  2020-11-12       Impact factor: 3.573

8.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

Authors:  Jessica A Fowler; Seint T Lwin; Matthew T Drake; James R Edwards; Robert A Kyle; Gregory R Mundy; Claire M Edwards
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

9.  Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in vivo study.

Authors:  Qing-Ping Wang; Xian-Ping Li; Min Wang; Li-Ling Zhao; Hui Li; Hui Xie; Zhi-Yong Lu
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

10.  Lung, Fat and Bone: Increased Adiponectin Associates with the Combination of Smoking-Related Lung Disease and Osteoporosis.

Authors:  Young Ju Suh; Merry-Lynn N McDonald; George R Washko; Brendan J Carolan; Russell P Bowler; David A Lynch; Gregory L Kinney; Jessica M Bon; Michael H Cho; James D Crapo; Elizabeth A Regan
Journal:  Chronic Obstr Pulm Dis       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.